Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderate to Severe Atopic Dermatitis (AD)

NCT03703102 is registered in ClinicalTrials.gov with Kyowa Kirin, Inc. as lead sponsor.

NCT NCT03703102
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03703102 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderate to Severe Atopic Dermatitis (AD)
Lead sponsor
Kyowa Kirin, Inc.
Phase
Phase 2
Overall status
Completed
Start date
October 22, 2018
Completion date
November 12, 2020
Enrollment
274 (actual)
Sites
58

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis